Credit rating agency, Crisil has assigned ‘AA/Stable’ rating to one of the two Rs 50 crore non-convertible debenture (NCD) programmes of IPCA Laboratories, while reaffirming its ratings on the company’s other Rs 50 crore NCD programme and bank facilities at ‘AA/Stable/CRISIL A1+’.
The ratings continue to reflect the company’s well-diversified business profile across therapeutic segments and geographies, established market position in the domestic formulations segment and international market, and integrated operations, which are expected to help the company maintain its healthy financial risk profile, which is marked by robust capital structure and healthy debt protection metrics.
Ipca Laboratories is engaged in manufacturing of active pharmaceutical ingredients and formulations. It operates in 110 countries and its export accounts for 50% of the company’s income. Worldwide the company is one of the largest suppliers of APIs and intermediates. The company holds leadership position in Anti-malarial and Rheumatoid Arthritis area.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1814.50 |
Dr. Reddys Lab | 1340.80 |
Cipla | 1476.45 |
Lupin | 2160.20 |
Zydus Lifesciences | 972.95 |
View more.. |